Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome (MDS)
Acute Myelogenous Leukemia (AML)
Fanconi Anemia

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Anti-Thymocyte Globulin (Rabbit)
Device: The CliniMACS device
Drug: G-CSF

First Posted Date: 2018-07-26

Last Posted Date: 2022-04-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT03600909

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

Phase 1

Active, not recruiting

Conditions: Severe Combined Immunodeficiency

Interventions: Drug: Anti-thymocyte globulin (rabbit)
Drug: Busulfan
Other: Donor Lymphocyte Infusion
Drug: Fludarabine
Drug: Thiotepa
Device: CliniMACS

First Posted Date: 2018-07-24

Last Posted Date: 2024-06-12

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 4

Registration Number: NCT03597594

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Cardiac Safe Transplants for Systemic Sclerosis

Phase 2

Terminated

Conditions: Systemic Sclerosis
Scleroderma

Interventions: Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mesna
Drug: rATG
Drug: Methylprednisolone
Drug: G-CSF
Biological: IVIg
Biological: Autologous Stem Cells

First Posted Date: 2018-07-20

Last Posted Date: 2020-08-12

Lead Sponsor: Northwestern University

Target Recruit Count: 9

Registration Number: NCT03593902

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

Conditions: Acute Lymphoblastic Leukemia
Immune System Diseases
Immunoproliferative Disorders

First Posted Date: 2018-07-20

Last Posted Date: 2021-12-03

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Registration Number: NCT03594162

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Phase 2

Recruiting

Conditions: FLT3-mutated Acute Myeloid Leukemia

Interventions: Drug: Midostaurin
Drug: Fludarabine
Drug: Cytarabine
Drug: Daunorubicin or idarubicin
Drug: Mitoxantrone
Drug: Etoposide

First Posted Date: 2018-07-19

Last Posted Date: 2024-04-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT03591510

Locations: 🇹🇷
Novartis Investigative Site, Istanbul, Turkey

CD19-Specific T Cells Post AlloSCT

Phase 1

Terminated

Conditions: B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Ph-Like Acute Lymphoblastic Leukemia
Refractory Small Lymphocytic Lymphoma
Recurrent Non-Hodgkin Lymphoma
Refractory B Acute Lymphoblastic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Interventions: Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2018-07-09

Last Posted Date: 2021-06-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT03579888

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia, in Relapse
Acute Lymphoblastic Leukemia, Refractory

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Device: CliniMACS
Biological: CD19- specific CAR engineered autologous T-cells (SJCAR19 product)

First Posted Date: 2018-06-29

Last Posted Date: 2024-10-30

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 24

Registration Number: NCT03573700

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Phase 1

Active, not recruiting

Conditions: Myeloid Diseases

Interventions: Drug: Antithymocyte globulin (Rabbit)
Drug: fludarabine
Radiation: total body irradiation
Drug: cyclophosphamide
Drug: Rituxan
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation

First Posted Date: 2018-05-22

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT03531736

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients

Phase 1

Conditions: Non Hodgkin Lymphoma

Interventions: Biological: IM19
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-05-17

Last Posted Date: 2018-07-16

Lead Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT03528421

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Phase 1

Completed

Conditions: CLL
Chronic Lymphocytic Leukemia
Lymphoma
Hodgkin Lymphoma
Multiple Myeloma

Interventions: Radiation: Total Body Irradiation
Procedure: Haploidentical Stem Cell Transplantation
Biological: CD56-Enriched Donor Lymphocyte Infusion
Drug: Bendamustine
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2018-05-14

Last Posted Date: 2024-11-11

Lead Sponsor: Noah Merin

Target Recruit Count: 20

Registration Number: NCT03524235

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy